MAGNEVIST 469 MG
GADOPENTETATE DIMEGLUMINE : 469 MG · DIN 01989987 · BAYER INC
Health Canada status: MARKETED
What is MAGNEVIST?
MAGNEVIST 469 MG contains GADOPENTETATE DIMEGLUMINE : 469 MG. It is listed in the Health Canada Drug Product Database under DIN 01989987, held by BAYER INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 10-Apr-2008. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MAGNEVIST used for?
Contrast enhancement during cranial/spinal MRI in adults and children; visualization of lesions with abnormal vascularity in head (extracranial) and neck in adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 01989987 |
|---|---|
| Brand name | MAGNEVIST |
| Generic / active ingredient | GADOPENTETATE DIMEGLUMINE : 469 MG |
| Manufacturer | BAYER INC |
| Strength | 469 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | V08CA01 GADOPENTETIC ACID |
| AHFS class | 36:89.00* ; See footnote |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 10-Apr-2008 |
| Original market date | 1992-12-31 00:00:00 |
How is it administered?
0.2 mL/kg (0.1 mmol/kg) by intravenous injection. Rate: 10 mL/min or bolus 10 mL/15 sec. Max single dose 20 mL. Follow with 5 mL saline flush.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15°C to 30°C. Sensitive to light. Keep container in outer carton.
How is it supplied?
20 mL, 15 mL, and 10 mL single-dose vials packaged in individual cartons.
Contraindications
Chronic severe kidney insufficiency (GFR <30 mL/min/1.73m2); acute kidney injury; neonates up to 4 weeks of age; known or suspected hypersensitivity.
Warnings and precautions
Risk of Nephrogenic Systemic Fibrosis (NSF) in renal impairment. Not for intrathecal use. Potential gadolinium accumulation in brain. Risk of seizures in susceptible patients.
What can be used instead?
Other Canadian products sharing ATC code V08CA01 GADOPENTETIC ACID. 1 of 3 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| GADOPENTETATE DIMEGLUMINE INJECTION | 469 MG | SOLUTION | AVIR PHARMA INC. | CANCELLED PRE MARKET | DIN 02497883 |
| GADOPENTETATE DIMEGLUMINE INJECTION, USP | 469 MG | SOLUTION | JUBILANT DRAXIMAGE INC. DBA JUBILANT RADIOPHARMA | CANCELLED PRE MARKET | DIN 02431513 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.